Aug 12, 2020
Milestone Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Corporate Update
May 14, 2020
Milestone Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Corporate Update
Mar 23, 2020
Milestone Pharmaceuticals Announces Topline Results from First-of-its-kind Phase 3 NODE-301 Trial of Etripamil for At-home Acute PSVT Treatment
Mar 06, 2020
Milestone Pharmaceuticals Reports Fourth Quarter and Year-end 2019 Financial Results and Provides Clinical and Corporate Update
Nov 13, 2019
Milestone Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Corporate Update
Oct 03, 2019
Milestone Pharmaceuticals Announces First Patient Enrolled in NODE-303 Open-label Safety Study of Etripamil in PSVT
Aug 08, 2018
Milestone Pharmaceuticals Announces First Patient Randomized in the Phase 3 NODE-301 Clinical Trial Evaluating Etripamil for Termination of Paroxysmal Supraventricular Tachycardia (PSVT) Episodes
Aug 08, 2018
Atrial Fibrillation Forecast In 19 Major Markets 2018-2028: Overview of the Classification and Patient Treatment Options for AF
Jun 18, 2018
Milestone Pharmaceuticals Announces Launch of OutsmartPSVT.com Supporting Patients with PSVT, a Common and Underdiagnosed Heart Disorder
May 08, 2018
New Research Demonstrates Online ECG Monitoring is More Effective than Offline Holter and Patch Methods to Detect Paroxysmal Arrhythmia
May 02, 2018
New Study Examines Online Vs Offline ECG Monitoring to Detect Difficult-to-Diagnose Arrhythmia
Nov 14, 2017
Patient Registry Shines Spotlight on PSVT, an Overlooked Heart Disorder
Oct 24, 2017
Milestone Pharmaceuticals Appoints Lorenz Muller as Chief Commercial Officer
Aug 01, 2017
Milestone Pharmaceuticals Closes $55 Million Series C Financing